Main Article Content
The potent anti-tumor activities of γδ T cells, their ability to produce pro-inflammatory cytokines, and their strong cytolytic activity have prompted the development of protocols in which γδ agonists or ex vivo-expanded γδ cells are administered to tumor patients. γδ T cells can be selectively activated by either synthetic phosphoantigens or by drugs that enhance their accumulation into stressed cells as aminobisphosphonates, thus offering new avenues for the development of γδ T cell-based immunotherapies. The recent development of small drugs selectively activating Vγ9Vδ2 T lymphocytes, which upregulate the endogenous phosphoantigens, has enabled the investigators to design the experimental approaches of cancer immunotherapies; several ongoing phase I and II clinical trials are focused on the role of the direct bioactivity of drugs and of adoptive cell therapies involving phosphoantigen- or aminobisphosphonate-activated Vγ9Vδ2 T lymphocytes in humans. In this review, we focus on the recent advances in the activation/expansion of γδ T cells in vitro and in vivo that may represent a promising target for the design of novel and highly innovative immunotherapy in patients with hematologic malignancies.
Downloads month by month
Download data is not yet available.
How to Cite
Meraviglia, S., La Mendola, C., Orlando, V., Scarpa, F., Cicero, G., & Dieli, F. (2011). Vγ9Vδ2 T cells as a promising innovative tool for immunotherapy of hematologic malignancies. Oncology Reviews, 4(4), 211-218. https://doi.org/10.4081/oncol.2010.211
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.